Direct comparison
GCP vs. GMP: What's the Difference?
GCP governs how clinical trials are conducted; GMP governs how the investigational product is manufactured. Compare scope, regulations, and oversight.
Ask about GCP vs. GMP: What's the Difference?
Answers are drawn from this comparison and the rest of the CASRAI corpus, with a link to every source.
Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this
How do GCP, GMP compare side by side?
The table below compares GCP, GMP across 12 procurement-relevant dimensions, from full name through relationship to glp.
Side-by-side comparison
| Dimension | GCP | GMP |
|---|---|---|
| Full name | Good Clinical Practice | Good Manufacturing Practice |
| What it governs | Conduct of the clinical trial itself — informed consent, protocol adherence, investigator/sponsor responsibilities, data integrity | Manufacturing, testing, and release of the drug substance/product, including investigational product (IMP) used in trials |
| Core guideline / US regulation | ICH E6(R2)/(R3); implemented via 21 CFR Part 312, with informed-consent/IRB requirements in 21 CFR Parts 50 and 56 | 21 CFR Parts 210 and 211 (drug cGMP) |
| Key international framework | ICH E6, harmonized across ICH regions (FDA, EMA, PMDA and others) | ICH Q7 (GMP for active pharmaceutical ingredients); EU GMP Annex 13/16 for investigational medicinal products |
| Who is regulated | Clinical investigators, sponsors, CROs, monitors, institutional review boards (IRBs) | Manufacturing facilities and the parties responsible for producing, testing, and releasing the product |
| Unit of compliance | Per trial/per site — protocol adherence and data integrity assessed per subject and site | Per facility/quality system — ongoing compliance of the manufacturing site and process |
| Oversight role | IRB/IEC, sponsor’s clinical monitor, GCP auditors | Quality unit; in the EU, a Qualified Person (QP) who certifies batch release |
| Core focus | Human-subject protection and the integrity/reliability of trial data | Product identity, purity, potency, and consistency |
| Key documentation | Trial master file (TMF), case report forms (CRFs), informed consent forms | Batch records, standard operating procedures (SOPs), certificates of analysis |
| FDA inspection program | Bioresearch Monitoring (BIMO) Program — inspects investigators, sponsors/monitors/CROs, IRBs | Separate drug-manufacturing surveillance and pre-approval inspections — not covered by BIMO |
| Phase-based flexibility | None — core informed-consent, protocol-adherence, and monitoring expectations apply from first-in-human onward | Yes — 21 CFR 210.2(c) exempts most Phase 1 investigational drugs from the full scope of Part 211 |
| Relationship to GLP | Distinct — GLP (21 CFR Part 58) governs the nonclinical/preclinical safety studies that precede human dosing | Distinct — GLP governs preclinical studies; GMP governs manufacture of the product used later in trials |
Common questions
Common questions about GCP vs GMP
Do I need GCP or GMP compliance for a clinical trial?
+
Both, for different parts of the trial. GCP (ICH E6, 21 CFR Part 312) governs how the trial is conducted — informed consent, protocol adherence, data integrity. GMP (21 CFR Parts 210/211) governs how the investigational product administered in the trial was manufactured. A trial needs both a GCP-compliant conduct plan and a GMP-manufactured product.
Can a site be GCP-compliant if the investigational product wasn’t manufactured under GMP?
+
No — they are separate but both required. A site can run flawless GCP-compliant trial conduct while the product itself was manufactured out of GMP compliance, and that is still a serious regulatory problem for the sponsor. The two compliance regimes are assessed and enforced independently.
Who inspects GCP vs. GMP?
+
FDA’s Bioresearch Monitoring (BIMO) Program inspects GCP compliance at clinical investigator sites, sponsors/monitors/CROs, and IRBs. GMP compliance at manufacturing facilities is inspected separately, through drug-manufacturing surveillance and pre-approval inspections that are not part of BIMO.
Is GCP the same as GLP?
+
No. GCP governs the human clinical trial itself. GLP (21 CFR Part 58) governs the nonclinical/preclinical safety and toxicology studies conducted before human dosing begins. See GLP vs. GMP for how GLP compares to manufacturing quality.
Does GMP apply differently in early-phase trials?
+
Yes. Under 21 CFR 210.2(c), most Phase 1 investigational drugs are exempt from the full scope of 21 CFR Part 211, with manufacturing controls expected to increase through later trial phases. GCP has no equivalent phase-based exemption — core conduct expectations apply from first-in-human trials onward.
Going deeper
